Should You Buy Acorda Therapeutics Inc (ACOR), Zafgen Inc (ZFGN), VIVUS, Inc. (VVUS)?
New York, NY – GDP INSIDER – 12/15/2014.
Acorda Therapeutics Inc (NASDAQ:ACOR) And Zafgen Inc (NASDAQ:ZFGN) disclosed initiation of Clinical Trials for post-stroke walking deficits and obesity respectively. Similarly, VIVUS, Inc. (NASDAQ:VVUS) disclosed favorable formulary positioning of its Qsymia. All the announcements have the potential to impact the shares.
Acorda Therapeutics Inc (NASDAQ:ACOR) said that the first patient for a stage three clinical study of dalfampridine has been enrolled for the post-stroke walking deficits treatment or PSWD. The company said that about three and a half million patients in America were suffering due to the issues of ongoing mobility.
Acorda Therapeutics Inc (NASDAQ:ACOR) believes that there was a big medical need in this segment since there were no medicines approved to improve walking of the people suffering from PSWD. The company stated that its stage two study of dalfampridine in PSWD delivered encouraging data, showing considerable improvements in walking speed.
The current stage three studies would have a similar patient population enrollment. It included a number of measurements to determine the dalfampridine impact in improving the walking.
Zafgen Inc (NASDAQ:ZFGN) disclosed that it has launched a phase 2b clinical study with beloranid, its lead product candidate, for the treatment of patients affected by severe obesity, as well as, type-2 diabetes. Zafagen indicated that the study would be a double-blind, randomized, placebo-controlled design in obese adults, who have a BMI of 30 – 60kg/m2.
Zafgen Inc (NASDAQ:ZFGN) said that the study would aspire to show weight loss of more than 6 – 12 month period. The company added that its objective was also to show improvements in glycemic control. It plans to enroll 150 patients from Australia’s 15 sites. It said that its primary efficacy endpoint was to transform the weight of total body from baseline while secondary endpoints key elements included modification in glycemic control, inflammatory markers, and parameters.
Could ZFGN Reverse From Here Or Will Momentum Continue? Get A Hint As To What’s Coming Next With A Free Trend Analysis Report
Hint As To What’s Coming Next With A Free Trend Analysis Report
VIVUS, Inc. (NASDAQ:VVUS) disclosed that Qsymia was the sole anti-obesity agent that was listed on the Performance Drug List of CVS/Caremark. VIVUS said that the purpose of preferred brand-name medicines listing were to help identify products, which were clinically appropriate, as well as, cost-effective.
VIVUS, Inc. (NASDAQ:VVUS) said that it was pleased that Qsymia was given the recognition of the preferred anti-obesity therapy on the CVS/Caremark PDL. The company believes that Qsymia would be an exceptional choice for patients suffering from obesity and complications linked with the disease. It said that Qsymia was given approval in America and was indicated as an addition to a reduced-calorie diet besides high physical activity for persistent adult weight management.
UltimateStockAlerts.com provides investors and traders with trading strategies via text message and email. To obtain text
message stock alerts service text the word ULTIMATE to 555888 from your cell phone.
UltimateStockAlerts continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
Disclosure: UltimateStockAlerts is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit www.UltimateStockAlerts.com website, for complete risks and disclosures.